This week’s MedTech funding rounds underscore accelerating innovation across metabolic health, precision oncology, and advanced drug-delivery platforms. Investors are backing companies driving clinical trials, scaling manufacturing, and preparing pivotal regulatory submissions.
Endogenex raises $50M to advance type 2 diabetes treatment
Endogenex has raised $50М in funding, setting the company up with sufficient funds to complete a pivotal trial of its type 2 diabetes treatment and support a regulatory filing for the endoscopic system with the FDA.
The Series C extension financing round was led by new lead investor Arboretum Ventures. Existing investors also participated, building on Endogenex’s previous $88М Series C fundraise, to a total $138М.
CEO Stacey Pugh
Last week’s tracker: Imperative Care, Thrombolex & more
Vaxess rebrands to Terrestrial Bio, raises $50M for GLP-1 patch
RA Capital led the financing for the company, with support from Engine Ventures, GHIC and SiteGround. Along with the financing and rebrand, the company will expand its manufacturing capabilities and establish a new headquarters.
These moves all come as it prepares for clinical trials and commercialization of its lead GLP-1 program.
CEO Rachel Sha
Hyperfine secures $40M loan facility
The loan facility, provided by Horizon Technology Finance Corporation, includes an initial funding of $15M at closing. The remaining $25M is available to support future commercial growth for the company.
This marks the latest cash infusion for Hyperfine, which brought in $17.5M through an offering last fall.
CEO Maria Sainz
OYMotion Technology secures 150M yuan in Series C funding
The company raised 150M yuan ($21.77M) led by the Shenzhen Brain Science and Brain-like Intelligence Industry Investment Fund under CICC Capital, bringing their total raised to $82.45M.
Several existing shareholders also participated in the round.
Founder and CEO Hualiang Ni
Virchow raises $4M to advance biopsy stewardship and precision oncology access
The working capital will be used to complete the development of the world’s first liquid specimen biorepository, the Virchow Vault, and deploy Biopsy Catchment® pilot programs at additional medical institutions across the United States.
The seed financing was led by Cerberus Ventures, supported by individuals, including pathologists and interventional radiologists who have used Virchow’s Crow’s Nest Biopsy Catchment System.
CEO Alexander Arrow
IceCure announces pricing of $4M registered direct offering
The company has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering.
In addition, in a concurrent private placement, IceCure will issue and sell unregistered Series B warrants to purchase up to 8,000,000 ordinary shares and Series C warrants to purchase up to 8,000,000 ordinary shares.
CEO Eyal Shamir
